Times of Israel | July 5, 2017

Israeli startup takes aim at Huntington’s disease

Mitoconix Bio nabs $20 million to develop a promising drug for treatment of neurodegenerative disorder

Fierce Biotech | jun 27, 2017

Mitoconix Bio hits $20M series A for neurodegenerative R&D

Preclinical startup Mitoconix Bio has secured a $20 million series A round for its research work on neurological disorders, including its lead candidate for Huntington’s disease.

YAHOO | June 27, 2017

Mitoconix Bio Raises $20 Million

Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies

GLOBES | 27 Jun, 2017

Neurological therapy co Mitoconix Bio raises $20m

The proceeds will be used to advance Mitoconix Bio’s lead product for the treatment of Huntington’s disease.